Tandem’s t:slim X2 shows improvements in type 1 and type 2 patients
Tandem Diabetes Care (NSDQ:TNDM) said studies of early use of its t:slim X2 insulin pump with Control-IQ advanced hybrid closed loop technology showed statistically significant improvements in sensor time in range (70-180 mg/dL) in people both type 1 and type 2 diabetes with no increase in hypoglycemia (<70 mg/dL).
One poster presentation at the conference reported outcomes from a retrospective analysis of users who uploaded at least 30 days of data to the t:connect web application before and after beginning use of the company’s Control-IQ technology as of March 11, 2020 and had at least 75% continuous glucose monitoring (CGM) use during this time (n=1,659). Use of Control-IQ technology led to a 10% increase (p<0.001) in median sensor time in range (70-180 mg/dL) to 78%, due to a 10% decrease in sensor time >180mg/dL and a 0.1% decrease of sensor time <70mg/dL. Users experienced 96% time in closed-loop automation.
The second poster reported outcomes from a retrospective analysis of users who uploaded at least 14 days of data to the t:connect web application by the same date and with the same percentage of CGM use. People with type 1 diabetes (n=2,896) showed a 9% increase in median sensor time in range (p<0.001), and a 0.04% decrease in sensor time <70 mg/dL (<0.001). Users with type 2 diabetes (n=144) experienced a 6% increase in median sensor time in range (p<0.001). Median time spent <70 mg/dL remained unchanged (0.2%). Both groups experienced 96% time in closed-loop automation.
The t:slim X2 insulin pump with Control-IQ technology uses glucose values from an integrated Dexcom G6 CGM with other variables such as insulin on board, to predict sensor glucose levels 30 minutes ahead and adjust insulin delivery accordingly.